Compare Liberty Energy Inc. Class A common stock (LBRT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Energy Inc. Class A common stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Liberty Energy Inc. Class A common stock trades at $17.99 (market cap $3.12B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.4× Liberty Energy Inc. Class A common stock's market cap, and Liberty Energy Inc. Class A common stock pays a 1.88% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Energy Inc. Class A common stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LBRT | SYRE | |
|---|---|---|
Market Cap | $3.12B | $7.52B |
Volume | 2,205,743 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $33.93 | $108.92 |
52-Week Low | $11.94 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.18B | $6.52B |
Dividend Yield | 1.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Liberty Energy (LBRT) trades at $19.11, up 0.68% today, with a bearish technical signal but strong analyst support. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue reached $4.01B in 2025, though net margins are thin at 2.92%. Valuation metrics like P/E of 25.82 and P/S of 0.75 suggest mixed attractiveness relative to profitability.
Outlook is cautiously optimistic given earnings momentum and a $28.38 consensus price target, but risks include margin pressure from rising costs and execution challenges in expanding into data center power. The stock's proximity to its 52-week low of $19.00 highlights downside vulnerability if Q3 results disappoint.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Liberty Energy Inc. Class A common stock
Liberty Energy provides completion services and technologies for onshore oil, natural gas, and geothermal producers in North America. It also offers distributed power and energy-storage solutions through Liberty Power Innovations.
Read more on LBRT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
